Exploring the Potential Drug Target and Biomarker SERF1A (SERF1_HUMAN)

Target Name: SERF1A

NCBI ID: G8293

SERF1A

Exploring the Potential Drug Target and Biomarker SERF1A (SERF1_HUMAN)

Introduction

Serf1a (SERF1_HUMAN) is a protein that plays a crucial role in the regulation of microtubules, which are dynamic organizing structures that are essential for various cellular processes. It is a member of the serine/threonine-tetratide repeat (STT) family, which is Characterized by a unique repeating sequence. Serf1a has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative disorders, and developmental defects.

Potential Drug Target

Serf1a has been shown to be involved in a variety of cellular processes that are crucial for human health and development. One of the primary functions of microtubules is to transport and organize intracellular molecules, including proteins, organelles, and vesicles. The regulation of microtubule dynamics and stability is critical for the proper functioning of these processes. Serf1a is involved in the regulation of microtubule stability and dynamics, which is essential for the proper functioning of intracellular transport and organization.

Serf1a has been shown to play a role in the regulation of mitosis, meiosis, and intracellular transport. It is involved in the assembly and disassembly of microtubules and in the regulation of microtubule dynamics. It has been shown to interact with various cellular components, including microtubules, kinesins, and microtubule-associated proteins.

Serf1a has also been shown to be involved in the regulation of cell division, apoptosis, and cellular signaling. It has been shown to play a role in the regulation of cell proliferation and differentiation, as well as in the regulation of cell death.

Potential Biomarkers

Serf1a has also been identified as a potential biomarker for various diseases, including cancer, neurodegenerative disorders, and developmental defects. Its involvement in these processes makes it an attractive target for drug development.

Serf1a has been shown to be involved in the regulation of cancer cell growth and metastasis. It has been shown to play a role in the regulation of cell adhesion and migration, which are critical processes for the development of cancer.

Serf1a has also been shown to be involved in the regulation of neurodegenerative disorders, including Alzheimer's disease and Parkinson's disease. It has been shown to play a role in the regulation of neurotransmitter synthesis and release, as well as in the regulation of neuronal excitability.

Serf1a has also been shown to be involved in the regulation of developmental defects, including Down syndrome and Fragile X syndrome. It has been shown to play a role in the regulation of chromosomal stability and the development of neural networks.

Conclusion

Serf1a (SERF1_HUMAN) is a protein that plays a crucial role in the regulation of microtubules and has been identified as a potential drug target and biomarker for various diseases. Its involvement in the regulation of intracellular transport, cell division, apoptosis, and cellular signaling makes it an attractive target for drug development. Further research is needed to fully understand the role of Serf1a in these processes and to develop effective treatments for various diseases.

Protein Name: Small EDRK-rich Factor 1A

Functions: Positive regulator of amyloid protein aggregation and proteotoxicity (PubMed:20723760, PubMed:22854022, PubMed:31034892). Induces conformational changes in amyloid proteins, such as APP, HTT, and SNCA, driving them into compact formations preceding the formation of aggregates (PubMed:20723760, PubMed:22854022, PubMed:31034892)

The "SERF1A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SERF1A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets